Insider Selling: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Sells 5,000 Shares of Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $56.30, for a total transaction of $281,500.00. Following the transaction, the director now owns 38,611 shares of the company’s stock, valued at $2,173,799.30. The trade was a 11.46 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Jeffrey William Henderson also recently made the following trade(s):

• On Monday, January 6th, Jeffrey William Henderson sold 10,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $50.01, for a total value of $500,100.00.

Halozyme Therapeutics Stock Up 0.9 %

Halozyme Therapeutics stock opened at $56.77 on Wednesday. Halozyme Therapeutics, Inc. has a one year low of $33.15 and a one year high of $65.53. The stock has a fifty day moving average of $51.00 and a 200 day moving average of $54.35. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36. The stock has a market cap of $7.22 billion, a PE ratio of 18.80, a price-to-earnings-growth ratio of 0.43 and a beta of 1.25.

Institutional Investors Weigh In On Halozyme Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. RPg Family Wealth Advisory LLC purchased a new stake in Halozyme Therapeutics during the third quarter valued at approximately $1,886,000. Segall Bryant & Hamill LLC grew its position in shares of Halozyme Therapeutics by 16.3% during the 3rd quarter. Segall Bryant & Hamill LLC now owns 355,176 shares of the biopharmaceutical company’s stock valued at $20,330,000 after acquiring an additional 49,856 shares during the period. Retirement Systems of Alabama increased its stake in shares of Halozyme Therapeutics by 23.5% in the 3rd quarter. Retirement Systems of Alabama now owns 389,268 shares of the biopharmaceutical company’s stock worth $22,282,000 after purchasing an additional 74,173 shares in the last quarter. South Street Advisors LLC purchased a new position in Halozyme Therapeutics during the third quarter valued at $9,812,000. Finally, Creative Planning lifted its position in Halozyme Therapeutics by 43.2% during the second quarter. Creative Planning now owns 37,291 shares of the biopharmaceutical company’s stock valued at $1,953,000 after purchasing an additional 11,249 shares in the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. HC Wainwright restated a “buy” rating and set a $70.00 price target on shares of Halozyme Therapeutics in a report on Tuesday. Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. Piper Sandler upped their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research note on Friday, January 10th. Wells Fargo & Company reduced their price target on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Finally, JMP Securities upped their price objective on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research report on Friday, November 1st. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $60.89.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.